SCHEMBL3604174

SCHEMBL3604174

CCOC(=O)c1ccc(N2CC3CN(C(=O)OC(C)(C)C)CCN3C2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.48
GPR119 Q8TDV5 2/20 0.45
ATM Q13315 1/20 0.44
SCN9A Q15858 1/20 0.43
RAB9A P51151 1/20 0.42
ALDH1A1 P00352 4/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30557779 1.00 USP30 (0.48) USP30GPR119ATMSCN9ARAB9A
SCHEMBL3612528 0.89 USP30 (0.55) USP30GPR119ATMSCN9AALDH1A1
SCHEMBL3609870 0.89 USP30 (0.50) USP30GPR119SCN9ANPSR1MEN1
SCHEMBL17068127 0.89 USP30 (0.50) USP30GPR119SCN9AALDH1A1MEN1
SCHEMBL22390314 0.87 GPR119 (0.53) USP30GPR119SCN9AALDH1A1MEN1
SCHEMBL22390313 0.87 GPR119 (0.53) USP30GPR119SCN9AALDH1A1MEN1
SCHEMBL17068128 0.87 USP30 (0.52) USP30GPR119SCN9AALDH1A1MEN1
SCHEMBL22390356 0.85 USP30 (0.45) USP30GPR119SCN9ARAB9AALDH1A1
SCHEMBL22390355 0.85 USP30 (0.45) USP30GPR119SCN9ARAB9AALDH1A1
SCHEMBL22390396 0.85 USP30 (0.52) USP30GPR119SCN9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A USP30 4815/4885GPR119 268/4885ATM 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.